The clopidogrel resistance can be attenuated with triple antiplatelet therapy in patients undergoing drug-eluting stents implantation

International Journal of Cardiology

Volumn 134, Issue 3, 2009, Pages 351-355

  Shim, Chi Young ^a   Yoon, Se Jung ^b   Park, Sungha ^a   Kim, Jung Sun ^a   Choi, Jong Rak ^a   Ko, Young Guk ^a   Choi, Donghoon ^a   Ha, Jong Won ^a   Jang, Yangsoo ^a   Chung, Namsik ^a   Shim, Won Heum ^a   Cho, Seung Yun ^a  

^a Yonsei University College of Medicine   (South Korea)

^b National Health Insurance Corporation   (South Korea)

Author keywords

Antiplatelet therapy; Aspirin resistance; Cilostazol; Clopidogrel resistance; Percutaneous coronary intervention

Indexed keywords

ACETYLSALICYLIC ACID; CILOSTAZOL; CLOPIDOGREL; HEPARIN;

ADULT; ANTICOAGULANT THERAPY; ARTICLE; CORONARY STENT; DRUG ELUTING STENT; FEMALE; HUMAN; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MULTIDRUG RESISTANCE; PERCUTANEOUS CORONARY INTERVENTION; PREVALENCE; PRIORITY JOURNAL; THROMBOSIS;

AGED; CARDIOVASCULAR SURGICAL PROCEDURES; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; DRUG-ELUTING STENTS; FEMALE; HUMANS; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; POSTOPERATIVE COMPLICATIONS; THROMBOSIS; TICLOPIDINE;

EID: 67349288529     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijcard.2008.02.016     Document Type: Article

References (23)

1. Cutlip D.E., Baim D.S., Ho K.K., et al. Stent thrombosis in the modern era: a pooled analysis of multicenter coronary stent clinical trials. Circulation 103 (2001) 1967-1971
2. Orford JL., Lennon R., Melby S., et al. Frequency and correlates of coronary stent thrombosis in the modern era: analysis of a single center registry. J Am Coll Cardiol 40 (2002) 1567-1572
3. Takahashi S., Kaneda H., Tanaka S., et al. Late angiographic stent thrombosis after sirolimus-eluting stent implantation. Circ J 71 (2007) 226-228
4. Ishikawa T., Mutoh M., Fuda Y., et al. Documented subacute stent thrombosis within thirty days after stenting with sirolimus-eluting stent (Cypher) for acute myocardial infarction: a Japanese single center retrospective non-randomized study. Circ J 70 (2006) 1091-1092
5. Biondi-Zoccai GG., Agostoni P., Sangiorgi G.M., et al. TRUE (Taxus in Real-Life Usage Evaluation) Study Investigators. Comparison of ticlopidine vs. clopidogrel in addition to aspirin after paclitaxel-eluting stent implantation: insights from the TRUE (Taxusin Real-life Usage Evaluation) Study. Int J Cardiol 108 (2006) 406-407
6. Eikelboom JW., Hirsh J., Weitz J.I., Johnston M., Yi Q., and Yusuf S. Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation 105 (2002) 1650-1655
7. Gum PA., Kottke-Marchant K., Welsh P.A., White J., and Topol E.J. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol 41 (2003) 961-965
8. Gurbel PA., Bliden K.P., Hiatt B.L., and O'Connor C.M. Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation 107 (2003) 2908-2913
9. Gurbel PA., Samara W.M., and Bliden K.P. Failure of clopidogrel to reduce platelet reactivity and activation following standard dosing in elective stenting: implications for thrombotic events and restenosis. Platelets 15 (2004) 95-99
10. Almsherqi ZA., McLachlan C.S., Mossop P., and Deng Y. Optimal antiplatelet treatment for percutaneous coronary intervention: clopidogrel vs. ticlopidine. Int J Cardiol 114 (2007) 101-102
11. Tanaka T., Ishikawa T., Hagiwara M., Onoda K., Itoh H., and Hidaka H. Effects of cilostazol, a selective cAMP phosphodiesterase inhibitor, on the contraction of vascular smooth muscle. Pharmacology 36 (1988) 313-320
12. Kunishima T., Musha H., Eto F., et al. A randomized trial of aspirin versus cilostazol therapy after successful coronary stent implantation. Clin Ther 19 (1997) 1058-1066
13. Ahn JC., Song W.H., Kwon J.A., et al. Effects of cilostazol on platelet activation in coronary stenting patients who already treated with aspirin and clopidogrel. Korean J Intern Med 19 (2004) 230-236
14. Lee SW., Park S.W., Hong M.K., et al. Triple versus dual antiplatelet therapy after coronary stenting. J Am Coll Cardiol 46 (2005) 1833-1837
15. Chen WH., Lee P.Y., Ng W., Tse H.F., and Lau C.P. Aspirin resistance is associated with a high incidence of myonecrosis after nonurgent percutaneous coronary intervention despite clopidogrel pretreatment. J Am Coll Cardiol 43 (2004) 1122-1126
16. Malinin A., Pokov A., Spergling M., et al. Monitoring platelet inhibition after clopidogrel with the VerifyNow-P2Y12(R) rapid analyzer: the VERIfy Thrombosis risk ASsessment (VERITAS) study. Thromb Res 119 (2007) 277-284
17. ® Cartridge for Monitoring Platelet Inhibition with Clopidogrel. Methods Find Exp Clin Pharmacol 28 (2006) 1-8
18. Muller I., Besta F., Schulz C., Massberg S., Schonig A., and Gawaz M. Prevalence of clopidogrel non-responders among patients with stable angina pectoris scheduled for elective coronary stent placement. Thromb Haemost 89 (2003) 783-787
19. Serebruany VL., Steinhubl S.R., Berger P.B., Malinin A.I., Bhatt D.L., and Topol E.J. Variability in platelet responsiveness to clopidogrel among 544 individuals. J Am Coll Cardiol 45 (2005) 246-251
20. Liu Y., Shakur Y., Yoshitake M., and Kambayashi Ji J. Cilostazol (pletal): a dual inhibitor of cyclic nucleotide phosphodiesterase type 3 and adenosine uptake. Cardiovasc Drug Rev. 19 (2001) 369-386
21. Okuda Y., Kimura Y., and Yamashita K. Cilostazol. Cardiovasc Drug Revs 11 (1993) 451-465
22. Sudo T., Ito H., Ozeki Y., and Kimura Y. Estimation of anti-platelet drugs on human platelet aggregation with a novel whole blood aggregometer by a screen filtration pressure method. Br J Pharmacol 133 (2001) 1396-1404
23. Woo SK., Kang W.K., and Kwon K.I. Pharmacokinetic and pharmacodynamic modeling of the antiplatelet and cardiovascular effects of cilostazol in healthy humans. Clin Pharmacol Ther 71 (2003) 246-252